Thanks for that Kayaker...

As per usual, Rob is very understated. He does not discuss the time factors involved with Shire, having to make a decision within under 60 days on a licensing agreement...or the fact that they have been in a collaborative study of BTI’s Transcend technology for a year now...to evaluate the efficacy of transporting their therapeutics across the BBB. So, Shire knows exactly how well the technology works and time is of the essence for them. He mentions Abbott, Astra/MedImmune and Texas Tech ( Herceptin sequel study) but nothing about the positive, intensifying competitive factor or the fact that 8 more major Pharmaceutical Co.’s are in late stage discussions on potential collaborative agreements. Nothing is said about multiple licensing of the technology or the global market potential.
 
One does get the imppression that he is incredibly well organized and confident.